RT @RichardPAConway: Sanchez-Bilboa at al. IV vs SC tocilizumab in 471 GCA patients. Equal efficacy. The authors report
Tweet Content
Sanchez-Bilboa at al. IV vs SC tocilizumab in 471 GCA patients. Equal efficacy. The authors report more adverse events with IV but actually this was purely due to longer follow up and per patient years it was the same. @RheumNow #EULAR2022 POS0272 https://t.co/2h7iIkMxjW
Show on Archive Page
On
Display in Search Results
On
PDQ
Off